| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate L Dang, DW White, S Gross, BD Bennett, MA Bittinger, EM Driggers, ... Nature 462 (7274), 739-744, 2009 | 4639 | 2009 |
| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486, 2019 | 1131 | 2019 |
| Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration JS Yu, CJ Wheeler, PM Zeltzer, H Ying, DN Finger, PK Lee, WH Yong, ... Cancer research 61 (3), 842-847, 2001 | 697 | 2001 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group H Okada, M Weller, R Huang, G Finocchiaro, MR Gilbert, W Wick, ... The Lancet Oncology 16 (15), e534-e542, 2015 | 692 | 2015 |
| Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment LM Liau, RM Prins, SM Kiertscher, SK Odesa, TJ Kremen, AJ Giovannone, ... Clinical Cancer Research 11 (15), 5515-5525, 2005 | 630 | 2005 |
| First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma LM Liau, K Ashkan, DD Tran, JL Campian, JE Trusheim, CS Cobbs, ... Journal of translational medicine 16, 1-9, 2018 | 545 | 2018 |
| Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy RM Prins, H Soto, V Konkankit, SK Odesa, A Eskin, WH Yong, SF Nelson, ... Clinical cancer research 17 (6), 1603-1615, 2011 | 521 | 2011 |
| An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR–dependent pathway D Guo, F Reinitz, M Youssef, C Hong, D Nathanson, D Akhavan, D Kuga, ... Cancer discovery 1 (5), 442-456, 2011 | 453 | 2011 |
| Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy WB Pope, RM Prins, M Albert Thomas, R Nagarajan, KE Yen, MA Bittinger, ... Journal of neuro-oncology 107, 197-205, 2012 | 376 | 2012 |
| EGFR signaling through an Akt-SREBP-1–dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy D Guo, RM Prins, J Dang, D Kuga, A Iwanami, H Soto, KY Lin, TT Huang, ... Science signaling 2 (101), ra82-ra82, 2009 | 364 | 2009 |
| Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens LM Liau, KL Black, RM Prins, SN Sykes, PL DiPatre, TF Cloughesy, ... Journal of neurosurgery 90 (6), 1115-1124, 1999 | 335 | 1999 |
| The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis D Guo, IJ Hildebrandt, RM Prins, H Soto, MM Mazzotta, J Dang, J Czernin, ... Proceedings of the National Academy of Sciences 106 (31), 12932-12937, 2009 | 268 | 2009 |
| 2-Hydroxyglutarate inhibits ATP synthase and mTOR signaling X Fu, RM Chin, L Vergnes, H Hwang, G Deng, Y Xing, MY Pai, S Li, L Ta, ... Cell metabolism 22 (3), 508-515, 2015 | 248 | 2015 |
| The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity RM Prins, N Craft, KW Bruhn, H Khan-Farooqi, RC Koya, R Stripecke, ... The Journal of Immunology 176 (1), 157-164, 2006 | 228 | 2006 |
| An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity KJ Williams, JP Argus, Y Zhu, MQ Wilks, BN Marbois, AG York, Y Kidani, ... Cancer research 73 (9), 2850-2862, 2013 | 198 | 2013 |
| Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma JP Antonios, H Soto, RG Everson, D Moughon, JR Orpilla, NP Shin, ... Neuro-oncology 19 (6), 796-807, 2017 | 194 | 2017 |
| Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 … LM Liau, K Ashkan, S Brem, JL Campian, JE Trusheim, FM Iwamoto, ... JAMA oncology 9 (1), 112-121, 2023 | 190 | 2023 |
| Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate RM Prins, TF Cloughesy, LM Liau New England Journal of Medicine 359 (5), 539-541, 2008 | 180 | 2008 |
| Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients RM Prins, X Wang, H Soto, E Young, DN Lisiero, B Fong, R Everson, ... Journal of immunotherapy 36 (2), 152-157, 2013 | 174 | 2013 |
| Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824 DD Vo, RM Prins, JL Begley, TR Donahue, LF Morris, KW Bruhn, ... Cancer research 69 (22), 8693-8699, 2009 | 153 | 2009 |
